Rheonix Presents Data to Back Flagship MDx Platform; Maps Regulatory Timeline for Two Tests

At AACC, Rheonix presented three research studies demonstrating its integrated sample prep and PCR testing platform. In addition, the company reiterated its intent to seek regulatory clearance in the US for a warfarin sensitivity genotyping test by the end of the year; followed by a regulatory submission in China for an HPV test.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.